Do analysts prefer STVN or FTRE?

Fortrea has a consensus price target of $22.00, suggesting a potential upside of 27.91%. Given Fortrea's higher probable upside, analysts plainly believe Fortrea is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86 Fortrea 1 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.36

Does the media prefer STVN or FTRE?

In the previous week, Fortrea had 2 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Fortrea and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.52 beat Fortrea's score of 0.42 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FTRE or SHC more profitable?

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Sotera Health 13.44% 40.12% 7.55%

Does the media prefer FTRE or SHC?

In the previous week, Fortrea had 2 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Fortrea and 6 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.12 beat Fortrea's score of 0.42 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sotera Health 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or FTRE?

In the previous week, Fortrea had 6 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for Fortrea and 2 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.84 beat Fortrea's score of 0.42 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer FTRE or MRVI?

In the previous week, Fortrea had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Fortrea and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.42 beat Fortrea's score of 0.42 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fortrea (FTRE) Competitors

$17.20 +0.18 (+1.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$17.12 -0.08 (-0.45%)

As of 09/11/2026 08:00 PM Eastern

Compare

FTRE vs. STVN, SHC, ADPT, ALMR, and MRVI

Should you buy Fortrea stock or one of its competitors? Fortrea's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Fortrea compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Stevanato Group has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

Stevanato Group has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.74	€158.21M	€0.56	37.47
Fortrea	$2.72B	0.60	-$986.20M	-$0.91	N/A

Stevanato Group has a net margin of 10.99% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Fortrea had 2 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Fortrea and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.52 beat Fortrea's score of 0.42 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortrea has a consensus price target of $22.00, suggesting a potential upside of 27.91%. Given Fortrea's higher probable upside, analysts plainly believe Fortrea is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Stevanato Group beats Fortrea on 9 of the 15 factors compared between the two stocks.

How does Fortrea compare to Sotera Health?

Fortrea (NASDAQ:FTRE) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Fortrea has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Sotera Health	13.44%	40.12%	7.55%

In the previous week, Fortrea had 2 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Fortrea and 6 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.12 beat Fortrea's score of 0.42 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sotera Health	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Sotera Health shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 15.4% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sotera Health has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.60	-$986.20M	-$0.91	N/A
Sotera Health	$1.16B	4.51	$77.94M	$0.57	32.23

Fortrea presently has a consensus target price of $22.00, suggesting a potential upside of 27.91%. Sotera Health has a consensus target price of $21.50, suggesting a potential upside of 17.04%. Given Fortrea's higher possible upside, equities analysts plainly believe Fortrea is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Sotera Health beats Fortrea on 12 of the 16 factors compared between the two stocks.

How does Fortrea compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 0.7% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fortrea has a net margin of -3.18% compared to Adaptive Biotechnologies' net margin of -20.73%. Fortrea's return on equity of 10.72% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Fortrea had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Fortrea and 1 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.77 beat Fortrea's score of 0.42 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adaptive Biotechnologies	Very Positive
Fortrea	Neutral

Adaptive Biotechnologies has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

Adaptive Biotechnologies currently has a consensus target price of $24.42, indicating a potential upside of 0.90%. Fortrea has a consensus target price of $22.00, indicating a potential upside of 27.91%. Given Fortrea's higher possible upside, analysts plainly believe Fortrea is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Adaptive Biotechnologies has higher earnings, but lower revenue than Fortrea. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	13.94	-$59.50M	-$0.41	N/A
Fortrea	$2.72B	0.60	-$986.20M	-$0.91	N/A

Summary

Adaptive Biotechnologies beats Fortrea on 8 of the 15 factors compared between the two stocks.

How does Fortrea compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Alamar Biosciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	26.08	-$29.82M	-$1.96	N/A
Fortrea	$2.72B	0.60	-$986.20M	-$0.91	N/A

In the previous week, Fortrea had 6 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for Fortrea and 2 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.84 beat Fortrea's score of 0.42 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Fortrea	-3.18%	10.72%	2.17%

Alamar Biosciences presently has a consensus price target of $31.80, indicating a potential upside of 14.02%. Fortrea has a consensus price target of $22.00, indicating a potential upside of 27.91%. Given Fortrea's higher possible upside, analysts clearly believe Fortrea is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Fortrea beats Alamar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Fortrea compare to Maravai LifeSciences?

Fortrea (NASDAQ:FTRE) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Fortrea has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Fortrea currently has a consensus target price of $22.00, indicating a potential upside of 27.91%. Maravai LifeSciences has a consensus target price of $6.83, indicating a potential upside of 4.65%. Given Fortrea's stronger consensus rating and higher probable upside, research analysts clearly believe Fortrea is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

50.3% of Maravai LifeSciences shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Fortrea had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Fortrea and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.42 beat Fortrea's score of 0.42 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a net margin of -3.18% compared to Maravai LifeSciences' net margin of -37.07%. Fortrea's return on equity of 10.72% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Maravai LifeSciences has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.60	-$986.20M	-$0.91	N/A
Maravai LifeSciences	$185.74M	9.13	-$130.77M	-$0.52	N/A

Summary

Fortrea beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTRE vs. The Competition

Export

Metric	Fortrea	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.64B	$9.74B	$7.16B	$12.85B
Dividend Yield	N/A	1.48%	2.57%	11.17%
P/E Ratio	-18.90	66.42	274.94	25.36
Price / Sales	0.60	108.85	686.57	116.78
Price / Cash	1.73	26.35	76.65	51.52
Price / Book	2.82	5.28	10.33	6.20
Net Income	-$986.20M	$56.67B	$3.50B	$358.50M
7 Day Performance	-2.82%	-2.15%	-3.32%	-2.35%
1 Month Performance	-3.48%	-1.93%	-0.53%	-3.23%
1 Year Performance	70.30%	25.04%	23.51%	8.79%

Fortrea Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTRE Fortrea	3.7875 of 5 stars	$17.20 +1.1%	$22.00 +27.9%	+70.3%	$1.64B	$2.72B	N/A	14,300	News Coverage
STVN Stevanato Group	2.855 of 5 stars	€20.45 -0.3%	N/A	-20.6%	€6.19B	€1.34B	36.52	6,010	News Coverage Positive News Analyst Forecast
SHC Sotera Health	4.2775 of 5 stars	$18.90 flat	$21.50 +13.8%	+14.5%	$5.39B	$1.16B	33.16	3,000	Positive News Analyst Forecast
ADPT Adaptive Biotechnologies	2.1074 of 5 stars	$24.28 flat	$24.42 +0.6%	+91.9%	$3.87B	$276.98M	N/A	790	Positive News
ALMR Alamar Biosciences	2.5466 of 5 stars	$30.80 flat	$31.80 +3.2%	N/A	$2.14B	$74.21M	N/A	222	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTRE) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortrea (FTRE) Competitors

FTRE vs. STVN, SHC, ADPT, ALMR, and MRVI

How does Fortrea compare to Stevanato Group?

Summary

How does Fortrea compare to Sotera Health?

Summary

How does Fortrea compare to Adaptive Biotechnologies?

Summary

How does Fortrea compare to Alamar Biosciences?

Summary

How does Fortrea compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortrea (FTRE) Competitors

FTRE vs. STVN, SHC, ADPT, ALMR, and MRVI

How does Fortrea compare to Stevanato Group?

Which has more volatility and risk, STVN or FTRE?

Which has better earnings & valuation, STVN or FTRE?

Is STVN or FTRE more profitable?

Does the media prefer STVN or FTRE?

Do analysts prefer STVN or FTRE?

Summary

How does Fortrea compare to Sotera Health?

Which has more volatility & risk, FTRE or SHC?

Is FTRE or SHC more profitable?

Does the media prefer FTRE or SHC?

Do institutionals & insiders hold more shares of FTRE or SHC?

Which has better valuation and earnings, FTRE or SHC?

Do analysts recommend FTRE or SHC?

Summary

How does Fortrea compare to Adaptive Biotechnologies?

Do institutionals and insiders have more ownership in ADPT or FTRE?

Is ADPT or FTRE more profitable?

Does the media prefer ADPT or FTRE?

Which has more volatility and risk, ADPT or FTRE?

Do analysts recommend ADPT or FTRE?

Which has preferable valuation and earnings, ADPT or FTRE?

Summary

How does Fortrea compare to Alamar Biosciences?

Which has stronger earnings & valuation, ALMR or FTRE?

Does the media prefer ALMR or FTRE?

Is ALMR or FTRE more profitable?

Do analysts recommend ALMR or FTRE?

Summary

How does Fortrea compare to Maravai LifeSciences?

Which has more risk & volatility, FTRE or MRVI?

Do analysts rate FTRE or MRVI?

Do insiders & institutionals believe in FTRE or MRVI?

Does the media prefer FTRE or MRVI?

Is FTRE or MRVI more profitable?

Which has stronger valuation and earnings, FTRE or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools